Novel Aβ peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease

[1]  T. D. Pugh,et al.  Mitochondrial DNA Mutations, Oxidative Stress, and Apoptosis in Mammalian Aging , 2005, Science.

[2]  W. K. Cullen,et al.  Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo , 2005, Nature Medicine.

[3]  J. D. McGaugh,et al.  Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice , 2005, Neuron.

[4]  W. H. Jordan,et al.  Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β , 2005, The Journal of Neuroscience.

[5]  L. Jenkins,et al.  Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD , 2005, Neurology.

[6]  T. Golde,et al.  The Aβ Hypothesis: Leading Us to Rationally‐Designed Therapeutic Strategies for the Treatment or Prevention of Alzheimer Disease , 2005, Brain pathology.

[7]  D. Wilcock,et al.  Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage , 2004, Journal of Neuroinflammation.

[8]  P. Seubert,et al.  Current progress in beta-amyloid immunotherapy. , 2004, Current opinion in immunology.

[9]  Stuart Maudsley,et al.  BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders , 2004, Trends in Neurosciences.

[10]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[11]  Peter J. Lenting,et al.  LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms , 2004, Neuron.

[12]  Jun Zhou,et al.  Absence of C1q Leads to Less Neuropathology in Transgenic Mouse Models of Alzheimer's Disease , 2004, The Journal of Neuroscience.

[13]  D. Quartermain,et al.  An Attenuated Immune Response Is Sufficient to Enhance Cognition in an Alzheimer's Disease Mouse Model Immunized with Amyloid-β Derivatives , 2004, The Journal of Neuroscience.

[14]  D. Wilcock,et al.  Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid Deposition , 2004, The Journal of Neuroscience.

[15]  B. Zlokovic.  Clearing amyloid through the blood–brain barrier , 2004, Journal of neurochemistry.

[16]  John D Lambris,et al.  Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. , 2004, Molecular immunology.

[17]  I. Ferrer,et al.  Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease , 2004, Brain pathology.

[18]  D. Selkoe,et al.  Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. , 2003, Annual review of pharmacology and toxicology.

[19]  D. Holtzman,et al.  Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice , 2003, Neurobiology of Disease.

[20]  D. Dickson,et al.  Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ-/- Knock-Out Mice , 2003, The Journal of Neuroscience.

[21]  B. Dubois,et al.  Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.

[22]  C. Lemere,et al.  Amyloid-Beta Immunization in Alzheimer's Disease Transgenic Mouse Models and Wildtype Mice , 2003, Neurochemical Research.

[23]  D. Diamond,et al.  Short-term β-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP+PS1 mice , 2003 .

[24]  P. Mcgeer,et al.  Is there a future for vaccination as a treatment for Alzheimer’s disease? , 2003, Neurobiology of Aging.

[25]  Dave Morgan,et al.  Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation , 2003, The Journal of Neuroscience.

[26]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[27]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.

[28]  R. Motter,et al.  Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G. Comi,et al.  Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. , 2003, Brain : a journal of neurology.

[30]  D. Holtzman,et al.  Aβ immunization and anti-Aβ antibodies: potential therapies for the prevention and treatment of Alzheimer’s disease , 2002 .

[31]  E. Masliah,et al.  Increased Extracellular Amyloid Deposition and Neurodegeneration in Human Amyloid Precursor Protein Transgenic Mice Deficient in Receptor-Associated Protein , 2002, The Journal of Neuroscience.

[32]  W. Klein.  Aβ toxicity in Alzheimer’s disease: globular oligomers (ADDLs) as new vaccine and drug targets , 2002, Neurochemistry International.

[33]  A. Cuello,et al.  Intracellular A-beta amyloid, A sign for worse things to come? , 2002, Molecular Neurobiology.

[34]  B. Hyman,et al.  Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy , 2002, The Journal of Neuroscience.

[35]  B. Hyman,et al.  Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[36]  Xin Wu,et al.  Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.

[37]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[38]  Brett Chromy,et al.  Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus , 2002, Brain Research.

[39]  F. Aloisi.  Immune function of microglia , 2001, Glia.

[40]  S. Younkin,et al.  Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition , 2001, Neurobiology of Aging.

[41]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Lemere,et al.  Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. , 2001, The American journal of pathology.

[43]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[44]  Ralph A. Nixon,et al.  Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.

[45]  D. Holtzman,et al.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.

[46]  P. Mathews,et al.  The Endosomal-Lysosomal System of Neurons in Alzheimer's Disease Pathogenesis: A Review , 2000, Neurochemical Research.

[47]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[48]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[49]  S. Gauthier,et al.  β-Amyloid precursor protein is detectable on monocytes and is increased in Alzheimer’s disease , 1999, Neurobiology of Aging.

[50]  B. Bradt,et al.  Complement-dependent Proinflammatory Properties of the Alzheimer's Disease β-Peptide , 1998, Journal of Experimental Medicine.

[51]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[52]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[53]  C. Glabe,et al.  Intracellular Aβ1-42 Aggregates Stimulate the Accumulation of Stable, Insoluble Amyloidogenic Fragments of the Amyloid Precursor Protein in Transfected Cells (*) , 1995, The Journal of Biological Chemistry.

[54]  C. Cotman,et al.  beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. , 1994, Journal of immunology.

[55]  P. Mcgeer,et al.  Complement activation by beta-amyloid in Alzheimer disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Bewick,et al.  EFFECT OF GRAFT PERFUSION WITH TWO CD45 MONOCLONAL ANTIBODIES ON INCIDENCE OF KIDNEY ALLOGRAFT REJECTION , 1989, The Lancet.

[57]  T. Springer,et al.  Contributions of the Mac-1 glycoprotein family to adherence-dependent granulocyte functions: structure-function assessments employing subunit-specific monoclonal antibodies. , 1986, Journal of immunology.

[58]  G. Viale,et al.  Glial fibrillary acidic protein immunoreactivity in normal and diseased human breast , 2005, Virchows Archiv A.

[59]  W. K. Cullen,et al.  Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. , 2005, Nature medicine.

[60]  R. Deane,et al.  LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. , 2004, Neuron.

[61]  R. Mrak,et al.  Microglia and neuroinflammation: a pathological perspective , 2004 .

[62]  D. Diamond,et al.  Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice. , 2003, Behavioral neuroscience.

[63]  D. Dickson,et al.  Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[64]  D. Holtzman,et al.  Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. , 2003, Neurobiology of disease.

[65]  D. Wilcock,et al.  Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[66]  W Blaine Stine,et al.  Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. , 2002, Brain research.

[67]  D. Holtzman,et al.  Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. , 2002, Advanced drug delivery reviews.

[68]  D. Holtzman,et al.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[69]  J. Hardy,et al.  A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. , 2000, Nature.

[70]  P. S. St George-Hyslop,et al.  A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. , 2000, Nature.

[71]  S. Gauthier,et al.  Beta-amyloid precursor protein is detectable on monocytes and is increased in Alzheimer's disease. , 1999, Neurobiology of aging.

[72]  H. Levine.  Quantification of beta-sheet amyloid fibril structures with thioflavin T. , 1999, Methods in enzymology.

[73]  T. Fleisher,et al.  Immune function. , 1997, Pediatrics in review.